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Introduction
1. INTRODUCTION
In  1985,  there  were  approximately  30  million  people  with
diabetes  worldwide;  by  1995,  this  number  had  escalated  to  135
million and by 2025, it is projected that there will be an increase in
the incidence of diabetes, affecting 300 million people. Most of the
expected increase will  be  in type 2  diabetes,  which accounts  for
>90% of cases of diabetes, while the incidence of Type 1 diabetes is
anticipated  to  remain  stable.  By  2025  the  countries  with  largest
number  of  people  with  diabetes  will  be  in  India  (>57  million,
prevalence  6%),  China  (>37  million,  prevalence  3.4%),  and  the
United States (>21 million, prevalence 8.9%).
Type 2 diabetes, a common disease that combines defects of
both insulin secretion and insulin action. It is a progressive illness
and most patients will eventually need more than two oral agents to
maintain adequate glucose control (Tripathi, 2004). Switching from
one drug to another  in  a patient  with poorly control  glycemia or
maximizing the dosage of an existing drug is only rarely hopeful.
Adding medications from different groups to the existing regimen
often  provides  more  effective  glycemic  control.  Several  of  the
available oral agents have been studied in the combination and have
been  shown to  further  improve  glycemic  control  when  compared
with monotherapy.
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Metformin  is  the  sole  member  of  the  biguanide  class  of
medications  in  the  United  States.  It  replaced  another  biguanide,
Phenformin,  which  was  removed  from  the  market  because  of  a
propensity for lactic acidosis in 1975 ( Bailey CJ, Turner RC, 1996.
Stumvoll  M,  Nurjhan  N,  1995).Available  in  short-acting  and
sustained-release formulations, it is one of the oldest, and indeed one
of the safest, medications used in the treatment of type 2 diabetes. 
Metformin exerts its effects primarily by decreasing hepatic
glucose  output  and  has  a  comparatively  lesser  effect  increasing
insulin sensitivity. Isotope studies suggest hepatic glucose output is
reduced primarily through inhibition of gluconeogenesis, which may
be reduced by as much as 75%. Patients using metformin also exhibit
lower fasting insulin concentrations. Most patients using metformin
lose weight, and as much as 88% of weight loss with metformin is
loss of body fat  mass. In patients with normal  renal function and
who  are  otherwise  healthy,  metformin  does  not  increase  plasma
lactic acid levels or rate of turnover (DeFronzo RA, Goodman AM,
1995). Weight loss occurring during initiation of metformin occurs
even without change in energy expenditure.
The major clinical effect of metformin is to decrease fasting
glucose levels, thereby reducing hemoglobin A1c (A1C). The degree
of  clinical  effect  varies  in  individual  patients,  but  most  patients
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experience a reduction in A1C of  ∼ 1.5 percentage points (Nathan
DM, Buse JB, 2006). Because metformin exerts its effects primarily
through  impairing  hepatic  gluconeogenesis,  it  is  primarily  an
antihyperglycemic agent, rather than a hypoglycemic agent, such as
insulin or sulfonylureas. As a result, the incidence of hypoglycemia
with  metformin  is  quite  low.  Metformin  has  additional  effects  of
modest  reduction  in  plasma  triglyceride  concentrations  resulting
from decreased production of very-low-density lipoprotein.
The  most  common  reported  adverse  reaction  to  metformin
therapy  is  gastrointestinal  upset,  including  nausea,  vomiting,
anorexia,  and  diarrhoea.  Most  patients  beginning  metformin
experience significant mild weight loss, most likely as a result  of
these effects. The gastrointestinal side effects gradually dissipate in
many patients;  thus,  metformin  is  generally  started  in  low doses,
such  as  500-850  mg  with  breakfast  and  supper,  and  are  titrated
slowly to the maximum dose of 2,550 mg daily. Some patients also
describe  a  metallic  taste.  Patient  compliance,  owing  in  part  to  a
slight  decrease in gastrointestinal side effects,  may be better  with
sustained-release  metformin  than  with  immediate-release
formulations.  Sustained-release  formulations  may be  administered
once or twice daily (Schwartz S, Fonseca V, 2006).
Lactic acidosis is a rare but potentially fatal complication of
metformin therapy. Incidence of this complication is very low: < 1
3
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case per 100,000 treated patients  (Salpeter  SR, Walsh JM, 2006).
Lactic acidosis can be caused by extremely high concentrations of
metformin in the bloodstream or by any condition that can induce
hypoxia or hepatic insufficiency, thus limiting the body's ability to
metabolize lactate. 
When lactic acidosis occurs,  it  is  generally in  patients who
have continued using metformin despite contraindications. Exclusion
criteria  for  metformin  therapy  include  renal  insufficiency  with
creatinine ≥ 1.5 mg/dl in men and 1.4 mg/dl in women, cardiac or
pulmonary insufficiency sufficient to cause reduction in peripheral
perfusion or central hypoxia, history of lactic acidosis, liver disease,
alcohol  abuse,  or  use of intravenous radiographic contrast  agents.
Because  of  metformin's  relatively  good  safety  profile,
association with weight loss or weight neutrality, and availability as
a generic formulation, it is commonly used as an initial agent in type
2  diabetes  when  lifestyle  modification  is  insufficient  to  control
glucose  levels.  Recent  American  Diabetes  Association  (ADA)
consensus guidelines have even suggested starting all eligible newly
diagnosed type 2 diabetic patients on metformin in conjunction with
efforts to modify lifestyle. 
Metformin  is  a  hydrophilic  drug  and  is  slowly  and
incompletely  absorbed  from  the  gastrointestianl  tract,  and  the
absolute bioavailability of a single 500mg dose is reported to be 50%
to 60% (Dunn&Piters, 1995). An obstacle to more successful use of
metformin  therapy  is  the  high  incidence  of  concomitant
4
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gastrointestinal  symptoms,  such as  abdominal  discomfort,  nausea,
and  diarrhoea  that  especially  occur  during  the  initial  weeks  of
treatment.  The  compound  also  has  relatively  short  plasma
elimination half life of 1.5 to 4.5 hours (Defang, Shufang, &Wei,
2005; Scheen, 1996). Side effects and the need for administration
two  or  three  times  per  day  when  larger  doses  are  required  can
decrease patient compliance.
A sustained release formulation that would maintain plasma
levels of the drug for 10 to 16 hours might be sufficient for once
daily  dosing  of  metformin.  So  SR  formulation  that  releases
metformin for 8 to 12 hrs may be suitable for once daily dosing. SR
products are needed for metformin to prolong its duration of action
and  improve  patient  compliance  (Medical  Economics  Co.,  1999;
Dunn& Peters, 1995).
Sulfonylureas include several medications that act on β-cells
to increase insulin release. They bind to the sulfonylurea receptor on
the  surface  of  the  β-cell  and  inhibit  potassium  efflux,  thus
depolarizing  the  β-cells  and  facilitating  insulin  release  (Aguilar-
Bryan  L,  Nichols  C,  1995).  First-generation  agents,  such  as
acetohexamide, chlorpropamide, and tolbutamide, have largely been
replaced  by  second-generation  sulfonylureas,  such  as  glyburide,
glipizde,  and  glimipiride,  which  have  improved  safety  profiles.
Because  sulfonylureas  act  by  stimulating  insulin  release  from β-
cells, patients without a sufficient number of β-cells, such as those
with type 1 diabetes, pancreoprivic diabetes, or later stages of type 2
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diabetes, does not respond to these medications. In patients who do
respond  to  them,  insulin  release  may  be  augmented  both  in  the
fasting state and postprandially. Although potencies can vary among
sulfonylureas,  they  tend  to  lower  A1C  to  a  similar  extent  to
metformin, ∼ 1.5 percentage points.
Hypoglycemia is the major detrimental effect of these agents.
Because  different  sulfonylureas  possess  different
pharmacotherapeutic  profiles,  there  are  differences  in  risk  of
hypoglycemic episodes among the different  agents.  Patients  using
sulfonylurea  medications  must  be  cautioned  regarding  the  signs,
symptoms,  and  risks  of  hypoglycemia  while  using  these
medications.  Elderly  patients  may  be  at  higher  risk  for
hypoglycemia,  and  patients  who  frequently  skip  meals  and
experience fluctuations in activity level may not be candidates for
these  medications.  Glyburide  appears  to  pose  a  higher  risk  of
inducing hypoglycemia than other members of this class, possibly
because it has a number of active metabolites and high affinity for
the  sulfonylurea  receptor  (Gangji  AS,  Cukierman  T,  2007).
Hypoglycemia may be recurrent, especially in patients with impaired
renal function. Most of these drugs are excreted by the kidney and
must  be  used  with  considerable  caution  in  patients  with  renal
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insufficiency.  Glipizide  is  often  preferred  in  cases  where  a
sulfonylurea is used in the setting of renal insufficiency. 
Another disadvantage of sulfonylureas is  the risk of  weight
gain. Many patients experience an increase ≥ 2 kg after initiation of
these  medications.  There  has  also  been  some  question  as  to  the
possibility that older sulfonylurea medications may increase risks of
coronary  artery  disease.  The  University  Group  Diabetes  Program
study did  find  an  increased  association  with tolbutamide use  and
risks  of  coronary  artery  events;  however,  this  finding  was  not
supported  in  the  U.K.  Prospective  Diabetes  Study  (Diabetes  24
(Suppl  1) 1975). It  is  also noteworthy that some patients with an
allergy  to  sulfonamide  medications  exhibit  cross-reactivity  with
sulfonylureas; therefore, these drugs are contraindicated in patients
with sulfa allergies. There may also be cross-reactivity with other
drugs,  such  as  carbonic  anhydrase  inhibitors,  loop  diuretics,  and
thiazide diuretics. 
An advantage of sulfonylureas, however, is cost. They are all
available in generic formulations at relatively low cost to patients,
which  make them more appealing  when  cost  is  a  major  issue  in
medication selection. A recent consensus statement from the ADA
and the European Association for the Study of Diabetes considered
sulfonylurea medications to be second-line agents.
Glipizide is an oral antidiabetic drug of the sulfonylurea class
that is used together with diet and exercise to reduce blood glucose
7
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in patients with type 2 diabetes. It stimulates the release of insulin
from the pancreas, directing the body to store blood sugar (Siconolfi-
Baez, 1990).
A Glipizide and metformin combination is used to treat high
blood sugar levels that are caused by type 2 diabetes. Normally, the
pancreas releases insulin after eating to help the body store excess
sugar for later use. This process occurs during normal digestion of
food. In type 2 diabetes, the body does not work properly to store the
excess  sugar  and the  sugar  remains in  the blood stream. Chronic
high blood sugar can lead to serious health problems in the future.
With two different modes of action, the combination of glipizide and
metformin  help  the  body  cope  with  high  blood  sugar  more
efficiently.
Conventional  drug  therapy  typically  involves  the  periodic
dosing of a therapeutic agent that has been formulated in a manner to
ensure  its  stability,  activity  and  bioavailability.  For  most  of  the
drugs,  conventional  methods  of  formulation  are  quite  effective.
However some drugs are unstable, toxic and have narrow therapeutic
range, exhibit extreme solubility problems, require localization to a
particular site in the body or require strict compliance or long term
use. In such cases a method of continuous administration of drug is
desirable to maintain fixed plasma drug levels. The goal in designing
sustained or controlled delivery is  to  reduce the frequency of the
dosing or to increase effectiveness of the drug by localization at the
site of action, reducing the dose required or providing uniform drug
8
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delivery,  so, controlled release dosage form is  that release one or
more  drugs  continuously  in  a  predetermined  pattern  for  a  fixed
period of  time,  either  systemically or  to  a  specified  target  organ.
Controlled release dosage forms provide a better control of plasma
drug  levels,  less  dosage  frequency,  less  side  effect,  increased
efficacy and constant delivery.
Tablets can be designed for use as immediate release products
by  suitable  modification  of  the  composition  and  manufacturing
process and can also be designed as modified release products, with
many different potential release patterns. 
However,  for  immediate  release  tablets,  tablet  disintegrants
play an important role in ensuring that the tablet matrix break up on
contact  with  the  fluid in  the  stomach to  allow the  release  of  the
active drug which then become available, in whole or in part,  for
absorption from the gastrointestinal tract(GIT). Although most drugs
are absorbed from the GIT after passing through the stomach, it is
nevertheless  important  with  immediate  release  products  that  the
tablet disintegrates properly in the stomach to release the drug and
allow it  to  be  absorbed quickly after  passing  through the pyloric
sphincter and on into duodenum and beyond.
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LITERATURE REVIEW
Aruna A, Nancy K (2000) developed a UV spectrophotometric
method based on the measurement of absorbance at 276 nm in pH6.8
phosphate buffer for glipizide, the method obeyed Beer’s law in the
concentration range 2-30µg/ml.
G Mubeen, Khalika Noor (2009) developed and validated for
the  estimation  of  metformin  hydrochloride  in  bulk  and  in  tablet
formulation based on the measurement of absorbance at 233nm in
pH6.8 phosphate buffer, the method obeyed Beer’s law in the range
of 2-18µg/ml.
Lewin  A,  Lipetz  R,  Schwartz  S  (2007)  compared  the
extended-release  metformin  in  combination  with  a  sulfonylurea
(glyburide) to sulfonylurea monotherapy in adult patients with type 2
diabetes. The purpose of this study was to compare the efficacy and
tolerability  of  extended-release  metformin  administered  with  a
sulfonylurea  monotherpy  in  patients  with  type  2  diabetes.  They
concluded that the combination of biguanide with sulfonylurea was
significantly more effective in lowering HbA and glucose levels than
sulfonylurea monotherapy in the adult patients with type 2 diabetes.
However, a significant increase in the prevalence of hypoglycaemia
was observed in the biguanide-sulfonylurea combination treatment
groups compared with the sulfonylurea monotherapy group.
Taipei,  Taiwan  (2006)  compared  the  Sustained-release
glipizide  therapy  to  immediate-release  glipizide  therapy  for
10
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treatment of type 2 diabetes mellitus in Chinese patients. The main
aim of the study was to compare the efficacy and tolerability of a
sustained-release  glipizide  (GSR)  formulation  with  those  of
immediate-release  glipizide  (GIR)  in  Chinese  patients  with  type2
diabetes  mellitus.  They  concluded  that  treatment  with  oral  GSR
(10mg QD) was not  significantly different  from that  of  treatment
with GIR (5mg BID) With respect to short term (12 weeks) FPG and
HbA(1c) Reductions in Chinese adults with type 2 diabetes mellitus
receiving treatment with a sulfonylurea.
M C Gohel, R K Parikh (2007) developed modified release
tablets  of  isoniazid  using  hydroxypropyl  methyl  cellulose  as  a
release  controlling  agent.  The  low-viscosity  grade  Hydroxypropyl
methyl cellulose, medium viscosity HPMC, and high-viscosity grade
HPMC were used to prepare the matrix tablets. The tablets prepared
by direct compression, were subjected to physical characterization
and  in-vitro drug  release  studies.  The  in-vitro  drug  release  was
carried out in pH6.8 alkaline dissolution medium. The polymer type
did not affect the flow of powder blend and the concentration of the
polymer.  The viscosity grade of HPMC and the drug release was
inversely correlated.
Abul Kalam Lutful Kabir, Tasbira Jesmeen (2008) formulated
the oral sustained-release Metformin hydrochloride matrix tablets by
using hydroxypropyl methyl  cellulose as  rate controlling polymer.
The  tablets  were  prepared  by  direct  compression  technique.  The
tablets  were  subjected  to  thickness,  weight  variation  test,  drug
content etc and showed satisfactory results. The results indicated that
11
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a decrease in release kinetics of the drug was observed by increasing
the polymer concentration.
D  Choudhary,  S  Kumar,  GD  Gupta  (2009)  attempted  to
improve  the  solubility  and  dissolution  of  glipizide  by  solid
dispersion (kneading) technique. Poloxamer 188 and Poloxamer 407
were used as the carriers. The glipizide-poloxamer solid dispersion
was characterized by FT-IR, Scanning Electron Microscopy and in-
vitro dissolution studies. The results show that Sds prepared in this
study were found to have better dissolution rates in comparison to
intact glipizide and physical mixture of PXM 188 and PXM 407.
Ganesh Chaulang, Piyush PateL, Sharwaree Hardikar (2009)
formulated  solid  dispersions  of  Furosemide  in  Sodium  Starch
Glycolate  using  Kneading  method.  This  study  shows  that  the
dissolution  rate  of  furosemide  can  be  enhanced  considerably  by
formulating  in  it  as  a  solid  dispersion  in  SSG  using  kneading
method. Incorporation of Superdisintegrants in the solid dispersions
played a critical role in dissolution enhancement. It may be feasible
to prepare suitable formulations of furosemide solid dispersions as
fast dissolving tablets.
Marina  Levina,  Fiona  Palmer,  (2005)  formulated  sustained
release  metformin  hydrochloride  tablets  by  direct  compression
technique  using  HPMC  as  rate  controlling  polymer.  The  matrix
formulations  were  compared  to  a  commercially  available  ER
metformin  hydrochloride  tablets  Glucophage  and  concluded  that
12
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matrix tablets prepared using Methocel K100M produced consistent
and robust extended release.
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PURPOSE AND PLAN OF WORK
AIMS AND OBJECTIVES 
♣ The  present  work  relates to  the  development  of  a
formulation for the effective treatment of Type2 Diabetes.
♣ The  formulation  involves  the  development  of  Metformin
hydrochloride (SR) and Gipizide (IR) as bilayer tablet.
♣ Metformin  hydrochloride  has  poor  compressibility  and
present formulation problems.
Present  study  aims  at  development  of  direct
compression  metformin  hydrochloride  using  different
excipients and enhancing the flow and compaction process,
which helps in development of bilayer tablet.
♣ Glipizide  have  very  low  solubility  and  as  a  result  low
dissolution rate. Solubility of Glipizide should be increased
in order to improve the dissolution rate.
♣ An effort  to increase the solubility and dissolution rate of
glipizide  in  order  to  increase  the  oral  bioavailability  is
needed.
The present work aims to evaluate the potential of the
solid  dispersion  technique  for  development  of  immediate
release using Sodium Starch Glycolate as hydrophilic carrier
for developing a bilayer tablet.
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PLAN OF WORK
1. Preparation  of  standard  graph  for  the  drug  Metformin
hydrochloride using UV spectrophotometry.
2. Preparation of Metformin hydrochloride SR tablets by direct
compression method.
3. Evaluation of the physical characteristics.
4. Compatibility study using Infra Red (IR) spectroscopy.
5. Tablet  assessed with respect  to  physical  parameters  such as
Friability  studies,  FT-IR  Studies,  Tablet  thickness,  Weight
variation  test,  Drug  content  assay,  Hardness,  Friability,  In-
Vitro release, dissolution kinetics.
6. Optimization  of  the  Metformin  hydrochloride  sustained
release tablets
7. Preparation of standard graph for the drug Glipizide using UV
spectrophotometry.
8. Preparation  of  Glipizide  immediate  release  tablets  by Solid
dispersion (kneading) method.
9. Evaluation of the physical characteristics.
10. Compatibility study using Infra Red (IR) spectroscopy.
11. Tablet  assessed with respect  to  physical  parameters  such as
Friability  studies,  FT-IR  Studies,  Tablet  thickness,  Weight
variation  test,  Drug  content  assay,  Hardness,  Friability,  In-
Vitro release, dissolution kinetics.
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12. Optimization of the Glipizide immediate release tablets.
13. Preparation  of  final  bilayer  tablets  using  optimized
formulations of  Metformin hydrochloride and Glipizide and
their evaluation.
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METFORMIN (USP 2000)
Chemical Formula:
C4H11N5 
Chemical Name 
1-(diaminomethylidene)-3, 3-dimethyl-guanidine 
Chemical Structure 
Molecular Weight 
129.164 g/mol 
Physical State 
Solid 
Melting Point 
223-2260C 
Water Solubility 
Freely soluble as HCl salt 
Isoelectric Point 
12.4 
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Drug Category 
• Hypoglycemic Agents
Dosage Forms 
• Extended release tablet (500 mg or 1000 mg) 
Pharmacology 
Metformin  is  an  antihyperglycemic  agent,  which  improves
glucose  tolerance  in  patients  with  type  2  diabetes,  lowering  both
basal and postprandial plasma glucose. Metformin is not chemically
or  pharmacologically  related  to  any  other  classes  of  oral
antihyperglycemic agents. Unlike sulfonylureas, metformin does not
produce  hypoglycemia  in  either  patients  with  type  2  diabetes  or
normal  subjects  and  does  not  cause  hyperinsulinemia.  With
metformin  therapy,  insulin  secretion  remains  unchanged  while
fasting  insulin  levels  and  daylong  plasma  insulin  response  may
actually decrease. 
Mechanism of Action 
Metformin's  pharmacologic  mechanisms  of  action  are
different  from  other  classes  of  oral  antihyperglycemic  agents.
Metformin decreases hepatic glucose production, decreases intestinal
absorption of glucose, and improves insulin sensitivity by increasing
peripheral glucose uptake and utilization. 
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Absorption 
Absorbed over  6 hours,  bioavailability  is  50  to  60% under
fasting conditions. Food delays absorption. 
Toxicity 
Acute oral toxicity (LD50): 350 mg/kg [Rabbit]. It would be
expected that adverse reactions of a more intense character including
epigastric  discomfort,  nausea,  and vomiting followed by diarrhea,
drowsiness,  weakness,  dizziness,  malaise  and  headache  might  be
seen. 
Drug Interactions 
(Clinical  Evaluation  of  Drug  Interactions  Conducted  with
metformin)
Furosemide - A single-dose, metformin-furosemide drug interaction
study  in  healthy  subjects  demonstrated  that  pharmacokinetic
parameters of both compounds were affected by co-administration.
Furosemide  increased  the  metformin  plasma  and  blood  Cmax by
22% and blood AUC by 15%,  without  any significant  change in
metformin renal clearance. When administered with metformin, the
Cmax  and  AUC  of  furosemide  were  31%  and  12%  smaller,
respectively, than when administered alone, and the terminal half-life
was decreased by 32%, without any significant change in furosemide
19
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renal clearance. No information is available about the interaction of
metformin and furosemide when co-administered chronically.
Nifedipine - A single-dose,  metformin-nifedipine  drug interaction
study  in  normal  healthy  volunteers  demonstrated  that  co-
administration of nifedipine increased plasma metformin Cmax and
AUC  by  20%  and  9%,  respectively,  and  increased  the  amount
excreted in the urine. Tmax and half-life were unaffected. Nifedipine
appears  to  enhance  the  absorption  of  metformin.  Metformin  had
minimal effects on nifedipine.
Cationic drugs - Cationic drugs (e.g., amiloride, digoxin, morphine,
procainamide,  quinidine,  quinine,  ranitidine,  triamterene,
trimethoprim, or vancomycin) that are eliminated by renal tubular
secretion  theoretically  have  the  potential  for  interaction  with
metformin  by  competing  for  common  renal  tubular  transport
systems.  Such interaction  between  metformin and oral  cimetidine
has been observed in normal healthy volunteers in both single- and
multiple-dose, metformin-cimetidine drug interaction studies, with a
60%  increase  in  peak  metformin  plasma  and  whole  blood
concentrations  and  a  40%  increase  in  plasma  and  whole  blood
metformin AUC. There was no change in elimination half-life in the
single-dose  study.  Metformin  had  no  effect  on  cimetidine
pharmacokinetics.
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GLIPIZIDE (USP 2000)
Chemical Formula 
C21H27N5O4S 
Chemical Name 
N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-
methyl-pyridine-2- carboxamide 
Chemical Structure 
N
NCH3
NH
S
NH
NH
O
O O O
Molecular Weight 
444.548 g/mol 
Physical State 
Solid 
Melting Point 
208-2090C 
Water Solubility 
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37.2 mg/L 
Isoelectric Point 
5.9 
Drug Category 
• Hypoglycemic Agents
Dosage Forms 
• Immediate-release oral tablets
• Extended-release oral tablets 
Pharmacology 
Glipizide, a second-generation sulfonylurea, is used with diet
to lower blood glucose in patients with diabetes mellitus type II. The
primary mode of action of glipizide in experimental animals appears
to  be  the  stimulation  of  insulin  secretion  from the  beta  cells  of
pancreatic islet tissue and is thus dependent on functioning beta cells
in  the  pancreatic  islets.  In  humans glipizide appears  to  lower  the
blood glucose acutely by stimulating the release of insulin from the
pancreas,  an  effect  dependent  upon  functioning  beta  cells  in  the
pancreatic islets. In man, stimulation of insulin secretion by glipizide
in response to a meal is undoubtedly of major importance. Fasting
insulin  levels  are  not  elevated  even  on  long-term  glipizide
administration, but the postprandial insulin response continues to be
enhanced after at least 6 months of treatment. Some patients fail to
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respond  initially,  or  gradually  lose  their  responsiveness  to
sulfonylurea drugs, including glipizide. 
Mechanism of Action 
Sulfonylureas likely bind to ATP-sensitive potassium-channel
receptors  on  the  pancreatic  cell  surface,  reducing  potassium
conductance  and  causing  depolarization  of  the  membrane.
Depolarization  stimulates  calcium  ion  influx  through  voltage-
sensitive  calcium channels,  raising  intracellular  concentrations  of
calcium ions, which induces the secretion, or exocytosis, of insulin. 
Absorption 
Gastrointestinal absorption is uniform, rapid, and essentially
complete. 
Toxicity 
The acute oral toxicity was extremely low in all species tested
(LD50 greater than 4 g/kg). Overdosage of sulfonylureas including
glipizide can produce hypoglycemia. 
Drug Interactions 
Immediate and Extended Release Tablets
The  hypoglycaemic  action  of  sulfonylurea’s  may  be
potentiated  by  certain  drugs  including  nonsteroidal  anti-
inflammatory agents, some azoles and other drugs that are highly
23
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bound  salicylates,  sulphonamides,  chloramphenicol,  probenecid,
coumarins,  monoamine  oxidase  inhibitors,  and  beta  adrenergic
blocking  agents.  When  such  drugs  are  administered  to  a  patient
receiving  glipizide,  the  patient  should  be  observed  closely  for
hypoglycaemia.  When  such  drugs  are  withdrawn  from  a  patient
receiving glipizide, the patient should be observed closely for loss of
control. In vitro binding studies with human serum proteins indicate
that glipizide binds differently than tolbutamide and does not interact
with salicylate or dicumarol. However, caution must be exercised in
extrapolating these findings to the clinical situation and in the use of
glipizide with these drugs.
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HYPROMELLOSE
Nonproprietary Names 
BP : Hypromellose 
JP : Hydroxypropylmethylcellulose 
PhEur: Hypromellosum
USP : Hypromellose
Synonyms 
            Benecel  MHPC;  hydroxypropyl  methyl  ether;  E464;
hydroxypropyl methylcellulose; HPMC; Methocel; methylcellulose
propylene glycol ether; merthyl hydroxypropylcellulose; Metolose ;
Pharmacoat ; Spectracel 6 ; Spectracel 15; Tylopur.
Chemical Name and CAS registry number 
Cellulose, 2-hydroxypropyl-methyl ether [9004-65-3]
Functional category 
Coating  agent;  film-former;  rate  –  controlling  polymer  for
sustained release; stabilizing agent; suspending agent; tablet binder;
viscosity – increasing agent. 
Viscosity (dynamic):
Wide  ranges  of  viscosity  types  are  commercially  available.
Aqueous  solutions  are  most  commonly  prepared,  although
hypromellose may also be  dissolved in  aqueous  alcohols  such as
ethanol  and propan-2-ol  provided the alcohol  content  is  less  than
50% w/w. Dichloromethane and ethanol mixtures may also be used
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to prepare viscous hypromellose solutions. Solutions prepared using
organic solvents tend to be more viscous; increasing concentration
also produces more viscous solutions; 
Methocel grade Nominal Viscosity (MPa
s)
K 100LVP 100 80-120
K4M 4000 3000-5600
K15MP 15000 12000-2100
K100MP 100 000 80 000-120 000
          
To  prepare  an  aqueous  solution,  it  is  recommended  that
hypromellose is dispersed and thoroughly hydrated in about 20-30%
of the required amount  of  water.  The water  should be vigorously
stirred  and  heated  to  80-90C,  then  the  remaining  hypromellose
added.  Cold  water  should  then be  added to  produce  the  required
volume.
When water miscible organic solvent such as ethanol, glycol,
or  mixtures  of  ethanol  and  dichloromethane  is  used,  the
hypromellose should first be dispersed into the organic solvent, at a
ratio of 5-8 parts of solvent to part of hypromellose. Cold water is
then added to produce the required volume. 
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CELLULOSE, MICROCRYSTALLINE
Nonproprietary Names
BP:         Microcrystalline cellulose
JP:          Microcrystalline cellulose
PhEur:    Cellulosum microcristallinum
USPNF: Microcrystalline cellulose
Synonyms
      Avicel  PH;  Celex;  cellulose  gel;  Celphere;  Ceolus  KG;
crystalline  cellulose;  E460;  Emcocel;  Ethispheres;  Fibrocel;
Pharmacel; Tabulose; Vivapur.
Chemical Name and CAS Registry Number
Cellulose [9004-34-6]
Empirical Formula and Molecular Weight
(C6H10O5)n ≈36 000. Where n ≈ 220.
Structural Formula
Functional Category
Adsorbent;  Suspending  agent;  Tablet  and  Capsule  Diluent;
Tablet Disintegrant.
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Applications in Pharmaceutical Formulation or Technology
         Microcrystalline cellulose is widely used in pharmaceuticals,
primarily as a binder/diluent in oral tablet and capsule formulations
where  it  is  used  in  both  wet-granulation  and  direct-compression
processes. In addition to its use as a binder/diluent, microcrystalline
cellulose  also  has  some  lubricant  and  disintegrant  properties  that
make it useful in tableting.
Uses of microcrystalline cellulose
Use Concentration (%)
Adsorbent 20–90
Antiadherent 5–20
Capsule binder/diluent 20–90
Tablet disintegrant 5–15
Tablet binder/diluent 20–90
Description
Microcrystalline  cellulose  is  a  purified,  partially
depolymerized cellulose that occurs as a white, odorless, tasteless,
crystalline powder composed of porous particles. It is commercially
available in different  particle sizes  and moisture grades that have
different properties and applications.
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MAGNESIUM STEARATE
Nonproprietary Names
BP :          Magnesium stearate
JP :          Magnesium stearate
PhEur :    Magnesii stearas
USPNF :  Magnesium stearate
Synonyms
   Magnesium Octadecanoate;  Octadecanoic  Acid,  Magnesium
Salt; Stearic Acid, Magnesium salt.
Chemical Name and CAS Registry Number
Octadecanoic acid magnesium salt [557-04-0]
Empirical Formula and Molecular Weight
C36H70MgO4 591.34
The USPNF 23 describes magnesium stearate as a compound
of magnesium with a mixture  of  solid  organic acids  that  consists
chiefly  of  variable  proportions  of  magnesium  stearate  and
magnesium  palmitate  (C32H62MgO4).  The  PhEur  2005  describes
magnesium stearate  as  a  mixture  of  magnesium salts  of  different
fatty acids consisting mainly of stearic acid and palmitic acid and in
minor proportions other fatty acids.
Structural Formula
[CH3(CH2)16COO]2Mg
Functional Category
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Tablet and Capsule Lubricant.
Applications in Pharmaceutical Formulation or Technology
           Magnesium stearate is widely used in cosmetics, foods, and
pharmaceutical  formulations. It is  primarily used as a lubricant in
capsule and tablet manufacture at concentrations between 0.25% and
5.0% w/w. It is also used in barrier creams.
Description
          Magnesium stearate is a very fine, light white, precipitated or
milled, impalpable powder of low bulk density, having a faint odor
of stearic acid and a characteristic taste. The powder is greasy to the
touch and readily adheres to the skin.
Typical Properties
Solubility: Practically insoluble in ethanol, ethanol (95%), ether and
water; slightly soluble in warm benzene and warm ethanol (95%).
Stability and Storage Conditions
          Magnesium stearate is stable and should be stored in a well-
closed container in a cool, dry place.
Incompatibilities
          Incompatible with strong acids, alkalis, and iron salts. Avoid
mixing with strong oxidizing materials. Magnesium stearate cannot
be  used  in  products  containing  aspirin,  some  vitamins,  and  most
alkaloidal salts.
                                                   
TALC
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Nonproprietary Names:
BP : Purified talc
JP : Talc
PhEur : Talcum
USPNF : Talc
Synonyms
Magsil osmanthus, Magsil star, powdered talc.
Chemical Name and CAS Registry Number
Talc [14807- 96- 6]
Structural Formula
Mg6 (Si2o5)4 (OH)4
Functional Category
Glidant,  Anticaking  agent,  Capsule  and  tablet  diluents  &
Tablet and capsule lubricant.
Applications in Pharmaceutical Formulation or Technology
It is widely used in oral solid dosage formulation as glidant
and diluents. It is also used in topical preparation of dusting powder,
although it should not be dust in surgical gloves. It is additionally
used to clarify liquid and is also used only for its lubricant properties
in cosmetics and food products.
                                                       
Uses of Talc
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Use Concentration (%)
Talcum powder 90–99
Tablet lubricant 1–10
Tablet & capsule diluents 5-30
Sodium Starch Glycolate
Nonproprietary Names
BP : Sodium starch glycollate
PhEur : Carboxymethylamylum natricum
USPNF : Sodium starch glycolate
Synonyms
Carboxymethyl  starch,  sodium  salt;  Explosol;  Explotab;
Glycolys; Primojel; starch carboxymethyl ether, sodium salt; Tablo;
Vivastar P.
Chemical Name and CAS Registry Number
Sodium carboxymethyl starch [9063-38-1]
Functional Category
Tablet and capsule disintegrant.
Applications in Pharmaceutical Formulation or Technology
32
Polymer Profile
Sodium  starch  glycolate  is  widely  used  in  oral
pharmaceuticals as a disintegrant in capsule and tablet formulations.
It is commonly used in tablets prepared by either direct compression
or wet-granulation processes. The usual concentration employed in a
formulation is between 2% and 8%, with the optimum concentration
about 4%, although in many cases 2% is sufficient. Disintegration
occurs by rapid uptake of water  followed by rapid and enormous
swelling.  Although  the  effectiveness  of  many  disintegrants  is
affected  by  the  presence  of  hydrophobic  excipients  such  as
lubricants, the disintegrant efficiency of sodium starch glycolate is
unimpaired. Increasing the tablet compression pressure also appears
to have no effect on disintegration time. Sodium starch glycolate has
also been investigated for use as a suspending vehicle.
Description
Sodium  starch  glycolate  is  a  white  to  off-white,  odorless,
tasteless, free-flowing powder. The PhEur 2005 states that it consists
of oval or spherical granules, 30–100 mm in diameter, with some
less-spherical granules ranging from 10–35 mm in diameter.
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MATERIALS AND EQUIPMENTS
MATERIALS 
Material Source
Metformin Granules India Limited, Hyderabad.  
Glipizide Franco-Indian Pharmaceuticals, Chennai.
HPMC K100m Himedia Laboratories, Mumbai.
HPMC K15m Himedia Laboratories, Mumbai.
HPMC K4m Himedia Laboratories, Mumbai.
Microcrystalline 
cellulose SD Fine Chemicals, Mumbai.
Sodium Starch 
Glycolate SD Fine Chemicals, Mumbai.
Magnesium Stearate SD Fine Chemicals, Mumbai.
Talc SD Fine Chemicals, Mumbai.
Silica Gel SD Fine Chemicals, Mumbai.
Equipments 
Equipment Model/company
Tablet punching machine Rimek mini press
UV-Visible spectrophotometer Jasco V-530
FT-IR spectrophotometer Jasco-FT-IR 8201 PC
Digital balance Denver instruments
Dissolution test apparatus Lab India Disso 2000
Pfizer hardness tester Scientific Engineering Corporation
Friability tester Remi equipments
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I.     ESTIMATION OF METFORMIN HYDROCHLORIDE
USING UV SPECTROPHOTOMETRY (G Mubeen, 2009)
a. Preparation of Stock Solution
Accurately  weigh  100mg  of  Metformin  hydrochloride  and
transfer to a 100ml volumetric flask and then add phosphate buffer
pH 6.8 to  dissolve the drug and then make up the volume up to
100ml with phosphate buffer pH6.8, this gives the stock solution l
(1000µg/ml).
b. Preparation of Standard Solution
From stock solution l, pipette out 1ml and transfer to 100ml
standard  volumetric  flask.  Make  up  the  volume  to  100ml  with
phosphate buffer pH6.8; this gives the stock solution ll (10µg/ml).
From the stock solution ll, pipette out 0.2, 0.4, 0.6, 0.8 and 10 ml
into 5 separate 10 ml volumetric flasks respectively, then make up
the volume up to the mark with phosphate buffer pH 6.8 to give 2, 4,
6, 8, and 10 µg/ml concentration solutions and the phosphate buffer
pH6.8 was taken as blank.
The absorbance was measured at 233nm and the graph was
plotted with concentration (µg/ml) vs absorbance.
II. ESTIMATION OF GLIPIZIDE USING UV 
SPECTROPHOTOMETRY (Aruna A, 2000)
a. Preparation of Stock Solution
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Accurately weigh 100mg of Glipizide and transfer to a 100ml
volumetric flask and then add phosphate buffer pH 6.8 and minimum
quantity  of  methanol  to  dissolve  the  drug  and  then  make  up  the
volume up to  100ml  with  phosphate  buffer  pH6.8,  this  gives  the
stock solution l (1000µg/ml).
b. Preparation of Standard Solution
From stock solution l, pipette out 1ml and transfer to 100ml
standard  volumetric  flask.  Make  up  the  volume  to  100ml  with
phosphate buffer pH6.8; this gives the stock solution ll (10µg/ml).
From the stock solution ll, pipette out 0.2, 0.4, 0.6, 0.8 and 10
ml into 5 separate 10 ml volumetric flasks respectively, then make
up the volume up to the mark with phosphate buffer pH 6.8 to give
2, 4, 6, 8, and 10 µg/ml concentration solutions and the phosphate
buffer pH6.8 was taken as blank. The absorbance was measured at
276nm and  the  graph  was  plotted  with  concentration  (µg/ml)  vs
absorbance.
III. COMPATIBILITY STUDIES
Before formulation of a drug substance into a dosage form, it
is essential that it should be chemically and physically characterized.
Compatibility  studies  give  the  information  needed  to  define  the
nature of the drug substances and provide a frame work for the drug
combination with pharmaceutical excipients in the fabrication of a
dosage form.
One of the requirements for the selection of suitable excipients
or  carrier  for  pharmaceutical  formulation  is  its  compatibility.
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Therefore  in  the  present  work,  a  study was  carried  out  by using
infrared  spectrophotometer  to  find  out  if  there  is  any  possible
chemical  interaction  between  Metformin  and  Glipizide  and  with
their excipients respectively.
Weighed amount of drug (3 mg) was mixed with 100 mg of
potassium bromide (dried at  40-50C). The mixture was taken and
compressed under  10-ton pressure  in  a hydraulic  press  to  form a
transparent pellet. The pellet was scanned from 4000-400cm-1 in IR
spectrophotometer (Silverstein).
IV. COMPOSITION OF VARIOUS TRIAL FORMULATIONS
FOR  THE  SR  LAYER  CONTAINING  METFORMIN
HYDROCHLORIDE
Metformin hydrochloride tablets are prepared by using direct
compression  technique.  Different  grades  of  HPMC  like  K4M,
K15M, and K100M are used as the rate controlling polymer or as
matrix formers.   Other polymers like microcrystalline cellulose is
used as water-insoluble filler, lubricants and glidants like Silica gel
and magnesium stearate  are  used  as  the  other  excipients.  All  the
ingredients  are  uniformly  mixed  and  subjected  for  direct
compression.
V. EVALUATION OF METFORMIN HYDROCHLORIDE SR
TABLETS
The  formulated  tablets  were  subjected  for  the  following
quality control tests:
a. Weight variation
b. Hardness
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c. Friability
d. Drug content uniformity
e. Disintegration
f. In vitro dissolution studies
a. Weight variation test
The USP weight variation test is run by weighing tablets 20
tablets individually, calculating the average weight and comparing
the individual tablet weight to the average. The tablets meet the USP
test if not more than 2 tablets are outside the percentage limit and if
no  tablet  differs  by  more  than  2  times  the  percentage  limit.  The
weight variation of tablets more than 324 mg allowed as per USP
limit is ±5%. 
b. Hardness test
Pfizer hardness tester was used for measuring the hardness of
formulated tablets. Five tablets were taken randomly and subjected
to test.
c. Friability
The pre weighed tablets are placed in the tumbling chamber
which is rotated for four minutes or for 100 revolutions. During each
revolution the tablets fall from a distance of six inches to undergo
shock. After 100 revolutions the tablets are again weighed and the
loss in weight indicates the friability. The acceptance limit of weight
loss should not be more than 0.5 to 1%.
d. Drug content Uniformity
Weigh and powder 20 tablets. Weigh accurately aquantity of
powder  containing about.1 gm of metformin,  shake with 70ml of
water for 15 min, dilute to 100 ml with water and filter. Dilute 10ml
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of the filtrate to 100ml with water. Further dilute 10 ml to 100ml
with water and measure the absorbance of the resulting solution at
the  maximum about  232nm.  Calculate  the  content  of  Metformin
hydrochloride taking 798 as a specific absorbance at 232nm.
e. Disintegration Test
Six  tablets  are  taken  in  disintegration  apparatus.  Six  glass
tubes that are 3 inches long open at the top and held against a 10
mesh screen at the bottom end of the basket rack assembly. To test
the  disintegration time one tablet  is  placed in each tube,  and the
basket rack is positioned in a 1litre beaker of water at 370C ± 20C
such that the tablets remain2.5 cm from the bottom of the beaker. A
standard motor driver device is used to move the basket assembly up
and  down  through  a  distance  of  5-6cm at  a  frequency  of  28-32
cycles per minute. To meet the USP standard all particles of tablet
must  pass  through  10  mesh  screen  in  the  time  specified.  For
uncoated tablets the USP time standard is 5minutes. But majority of
tablets have maximum disintegration time for 30 minutes.
f. In vitro Dissolution Study
The release of Metformin hydrochloride from the SR tablets
was  studied  in  900  ml  of  dissolution  medium  using  a  USP
dissolution paddle assembly (Lab India Disso 2000) instrument at 50
rpm and  37±0.5°C.  The  dissolution  medium used  was  phosphate
buffer pH6.8.
Samples  of  dissolution medium were  withdrawn at  suitable
time interval and was then determined spectrophotometrically at 233
nm. Graph was plotted with time vs percentage drug released.
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VI. COMPOSITION OF VARIOUS TRIAL FORMULATIONS
FOR THE IR LAYER CONTAINING GLIPIZIDE
Glipizide tablets are prepared by using kneading method of
solid  dispersion  technique.  Glipizide  and sodium starch  glycolate
were  triturated  using  a  small  volume  of  methanol-water  (1:1)
solution to obtain a thick paste, which was kneaded for 30 min and
then dried at 40oC in an oven. The dried mass was then pulverized,
passed through mesh no 30.
The prepared solid dispersion is mixed with other ingredients
like  microcrystalline  cellulose;  talc and colouring  agent  tartrazine
are added and uniformly fixed.  100mg is accurately weighed from
the above mixture and the tablets were punched using Rimek mini
press.
VII. EVALUATION OF GLIPIZIDE IR TABLETS
The  formulated  tablets  were  subjected  for  the  following
quality control tests:
a. Weight variation
b. Hardness
c. Friability
d. Drug content uniformity
e. Disintegration
f. In vitro dissolution studies
a. Weight variation test
The USP weight variation test is run by weighing tablets 20
tablets individually, calculating the average weight and comparing
the individual tablet weight to the average. The tablets meet the USP
test if not more than 2 tablets are outside the percentage limit and if
no  tablet  differs  by  more  than  2  times  the  percentage  limit.  The
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weight variation of tablets less than 130 mg allowed as per USP limit
is ±10%. 
b. Hardness test
Pfizer hardness tester was used for measuring the hardness of
formulated tablets. Five tablets were taken randomly and subjected
to test.
c. Friability
The pre weighed tablets are placed in the tumbling chamber
which is rotated for four minutes or for 100 revolutions. During each
revolution the tablets fall from a distance of six inches to undergo
shock. After 100 revolutions the tablets are again weighed and the
loss in weight indicates the friability. The acceptance limit of weight
loss should not be more than 0.5 to 1%.
d. Drug content Uniformity
The prepared tablets containing glipizide was tested for drug
content uniformity. Tablets were dissolved in 100 ml of methanol in
100 ml volumetric flask which was previously clean and dry. This
solution after suitable dilution was measured for absorbance at 276
nm in a Jasco V530 UV visible spectrophotometer.
e. Disintegration Test
Six  tablets  are  taken  in  disintegration  apparatus.  Six  glass
tubes that are 3 inches long open at the top and held against a 10
mesh screen at the bottom end of the basket rack assembly. To test
the  disintegration time one tablet  is  placed in each tube,  and the
41
Experimental Section 
basket rack is positioned in a 1litre beaker of water at 370C ± 20C
such that the tablets remain2.5 cm from the bottom of the beaker. A
standard motor driver device is used to move the basket assembly up
and  down  through  a  distance  of  5-6cm at  a  frequency  of  28-32
cycles per minute. To meet the USP standard all particles of tablet
must  pass  through  10  mesh  screen  in  the  time  specified.  For
uncoated tablets the USP time standard is 5minutes. But majority of
tablets have maximum disintegration time for 30 minutes.
f. In vitro Dissolution Study
The release of glipizide from the tablets was studied in 900 ml
of  dissolution  medium using  a  USP dissolution  paddle  assembly
(Lab India Disso 2000) instrument  at  50 rpm and 37±0.5°C. The
dissolution medium used was phosphate buffer pH6.8.
Samples  of  dissolution medium were  withdrawn at  suitable
time interval and was then determined spectrophotometrically at 276
nm. Graph was plotted with time vs percentage drug released.
VIII. Formulation of Bilayer Tablet of Metformin Hydrochloride
(SR) and Glipizide (IR)
Final  bilayer  tablets  were  prepared  using  optimized
formulations  of  Metformin  hydrochloride  (F3)  and Glipizide  (F4).
Initially  Metformin  hydrochloride  was  compressed  very  slightly
followed by addition of Glipizide to it and compressed finally to get
a bilayer tablet (F7).
IX.EVALUATION  OF  BILAYER  TABLET  CONTAINING
METFORMIN  HYDROCHLORIDE  (SR)  AND  GLIPIZIDE
(IR) TABLETS
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The  evaluation  tests  performed  for  the  Metformin
hydrochloride SR tablets and Glipizide IR tablets are repeated for
the  bilayer  tablet  containing  Metformin  hydrochloride  (SR)  and
Glipizide (IR).
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I.  ESTIMATION  OF  METFORMIN  HYDROCHLORIDE
USING UV SPECTROPHOTOMETRY
Metformin  hydrochloride  was  estimated  using  phosphate
buffer pH6.8 and measured at 233nm using UV spectrophotometry.
It obeyed the Beer’s law in the range of 2-10µg/ml. Slope was found
to be 0.0784 and the correlation coefficient was found to be 0.9999
and the results were given in table 1.
Table 1: Estimation of Metformin hydrochloride measured at
233nm using UV spectrophotmetry
S.
No
Concentration
(µg/ml)
Absorbance at
233nm
1 0 0.000
2 2 0.151
3 4 0.312
4 6 0.471
5 8 0.625
6 10 0.781
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Fig 1: Estimation of Metformin hydrochloride measured at
233nm using UV spectrophotmetry.
II. ESTIMATION OF GLIPIZIDE USING UV 
SPECTROPHOTOMETRY
Glipizide was  estimated  using  phosphate  buffer  pH6.8  and
measured  at  276nm  using  UV spectrophotometry.  It  obeyed  the
Beer’s law in the range of 2-10µg/ml. Slope was found to be 0.023
and the correlation coefficient was found to be 0.9997 and the results
were given in table 2.
Table 2: Estimation of Glipizide measured at 276nm using UV
spectrophotmetry
S.
No Concentration (µg/ml) Absorbance at 276nm
1 0 0.000
2 2 0.048
3 4 0.091
4 6 0.141
5 8 0.184
6 10 0.231
0 2 4 6 8 10 12
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Fig 2: Estimation of Glipizide measured at 276nm using UV
spectrophotmetry.
III. COMPATIBILITY STUDIES
Fig3: Infra red spectrum of Metformin hydrochloride
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NH2 10 amine  stretch  occurs  between  3500-3400  cm-1
(Silverstein). In the above figure primary amine was found at peak
12 at 3399.89 cm-1.
Aliphatic CH stretch occurs between 2962-2872 cm-1. In the 
above figure the aliphatic CH stretch was found at peak 20 at 2963 
cm-1.
Fig 4: Infra red spectrum of Metformin hydrochloride and 
HPMC
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NH2 10 amine stretch occurs between 3500-3400 cm-1. In the 
above figure primary amine was found at peak 8 at 3482.81 cm-1.
Aliphatic CH stretch occurs between 2962-2872 cm-1. In the 
above figure the aliphatic CH stretch was found at peak 15 at 2972 
cm-1.
Fig 5: Infra red spectrum of Metformin hydrochloride and 
Micro crystalline cellulose.
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NH2 10 amine stretch occurs between 3500-3400 cm-1. In the 
above figure primary amine was found at peak 10 at 3497 cm-1.
Aliphatic CH stretch occurs between 2962-2872 cm-1. In the 
above figure the aliphatic CH stretch was found at peak 16 at 2902 
cm-1.
Fig 6: Infra red spectrum of Metformin hydrochloride and 
Magnesium stearate
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NH2 10 amine stretch occurs between 3500-3400 cm-1. In the 
above figure primary amine was found at peak 11 at 3464 cm-1.
Aliphatic CH stretch occurs between 2962-2872 cm-1. In the 
above figure the aliphatic CH stretch was found at peak 17 at 2925 
cm-1.
Fig 7: Infra red spectrum of Glipizide
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S=O stretch of sulphonamides occurs at 1370-1335 cm-1. In the 
above spectrum S=O stretch can be noticed at peak number 24 at 
1342 cm-1.
C=O stretch of amide occurs at 1689.34 cm-1.
Aliphatic CH stretch occurs at 2962 and 2872 cm-1. In the above 
spectrum the CH stretch can be noticed at peak 11 at 2938 cm-1.
Fig 8: Infra red spectrum of Glipizide and microcrystalline
cellulose
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S=O stretch of sulphonamides occurs at 1370-1335 cm-1. In the 
above spectrum S=O stretch can be noticed at peak number 49 at 
1346 cm-1.
C=O stretch of amide occurs at 1673.91.34 cm-1.
Aliphatic CH stretch occurs at 2962 and 2872 cm-1. In the above 
spectrum the CH stretch can be noticed at peak 20 at 2935 cm-1.
Fig 9: Infra red spectrum of Glipizide and Sodium starch
glycolate
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S=O stretch of sulphonamides occurs at 1370-1335 cm-1. In the 
above spectrum S=O stretch can be noticed at peak number 51 at 
1353 cm-1.
C=O stretch of amide occurs at 1689.34 cm-1.
Aliphatic CH stretch occurs at 2962 and 2872 cm-1. In the above 
spectrum the CH stretch can be noticed at peak 21 at 2892 cm-1.
Fig 10: Infra red spectrum of Glipizide and Metformin 
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S=O stretch of sulphonamides occurs at 1370-1335 cm-1. In the 
above spectrum S=O stretch can be noticed at peak number 32 at 
1334.5 cm-1.
C=O stretch of amide occurs at 1689.34 cm-1.
Aliphatic CH stretch occurs at 2962 and 2872 cm-1. In the above 
spectrum the CH stretch can be noticed at peak 16 at 2938 cm-1.
IV. COMPOSITION OF VARIOUS TRIAL FORMULATIONS
FOR  THE  SR  LAYER  CONTAINING  METFORMIN
HYDROCHLORIDE
Metformin hydrochloride sustained release formulations with
HPMC  as  rate  controlling  polymer  were  prepared  by  direct
compression technique and the composition of the sustained release
formulations was given in table 3.
Table 3: Composition of Various Trial Formulations for the SR
Layer Containing Metformin hydrochloride
Formulation code F1 F2 F3
Metformin(mg) 500 500 500
HPMC K100M(mg) 360 - -
HPMC K15M(mg) - 360 -
HPMC K4M(mg) - - 360
Micro crystalline 
cellulose(mg) 125 125 125
Silica gel(mg) 5 5 5
Magnesium stearate(mg) 5 5 5
Total weight(mg) 995 995 995
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V. EVALUATION OF METFORMIN HYDROCHLORIDE SR
TABLETS
a. Weight variation test
In a weight variation test,  the pharmacopoeial  limit  (United
States Pharmacopoeia, 2000) for the percentage deviation more than
324mg  is  ±  5%.  The  average  percentage  deviation  of  all  tablet
formulations was found to be within the above limit, and hence all
formulations  passed  the  uniformity  of  weight  as  per  official
requirements of the United States Pharmacopoeia (2000). The results
were shown in table 4.
Table 4: Weight variation of Metformin hydrochloride tablets
S.
No
.
Formulatio
n code
Weight
range of  20
Tablets
Average
weight
Limit
range
(±7.5%)
1 F1 973-997mg 985.45mg 936.2-1034.7
2 F2 971-998mg 989mg 939.5-1038.4
3 F3 975-998mg 988mg 938.6-1037.4
b. Hardness test
Formulated Metformin hydrochloride SR tablets were tested
for hardness using Pfizer hardness tester. The results of hardness test
were given in table 5.
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Table 5: Hardness test of Metformin hydrochloride SR tablets
S. No. Formulation code Hardness (kg/cm2)
1 F1 7
2 F2 6.5
3 F3 5.5
c. Friability
Tablet  hardness  is  not  an  absolute  indicator  of  strength
(Banker & Ander, 1987). Another measure of a tablet’s strength is
friability. Conventional compressed tablets that lose less than 1% of
their  weight  are  generally  considered  acceptable.  In  the  present
study, the percentage of friability for all the formulations was below
1%, indicating that  the  friability  was  within the  prescribed  limits
(Banker & Ander, 1987). The results of friability test were given in
table 6.
Table 6: Friability test of Metformin hydrochloride SR tablets
S.
No. Formulation code Friability (%)
1 F1 0.46
2 F2 0.59
3 F3 0.52
b. Drug content Uniformity
Metformin hydrochloride SR tablets  are tested for  the drug
content as prescribed in the USP. Good uniformity in content was
found  among  different  formulations  and  the  percentage  of  drug
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content  was  more  than  99%.  Percentages  of  drug  present  in  the
tablets were given in the table 7.
Table 7: Drug content test of Metformin hydrochloride SR 
tablets
S. No. Formulation
code
Amount of Metformin
hydrochloride
Amount in mg Amount inpercentage
1 F1 500 100
2 F2 496 99.2
3 F3 501 100.2
c. Disintegration Test
Disintegration test was carried out for formulated Metformin
hydrochloride SR tablets using the disintegration test apparatus as
prescribed in USP. The results of the disintegration test were given in
table 8.
Table 8: Disintegration test of Metformin 
Hydrochloride SR tablets
S.
No. Formulation code Disintegration Time
1 F1 35min
2 F2 28 min
3 F3 20 min
d. In vitro Dissolution Study
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Figure  11  shows  the  dissolution  profile  of  the  prepared
Metformin hydrochloride formulations. All three dissolution profiles
appear to be similar.
Metformin HCl is highly soluble in water with poor inherent
compressibility. Moreover its high dose (500mg) poses a significant
challenge  for  developing  an  SR  dosage  form.  For  obtaining  a
desirable  drug  release  profile,  cost  effectiveness,  and  broader
regulatory acceptance, HPMC was chosen as the release-controlling
polymer.  HPMC  is  a  mixed  alkyl  hydroxyalkyl  cellulose  ether
containing methoxyl  hydroxypropyl groups. The hydration rate of
HPMC depends on the nature of these substituents. Specifically the
hydration  rate  of  HPMC  increases  with  an  increase  in  the
hydroxypropyl  content  and  the  solubility  of  HPMC  is  pH
independent (Hogan, 1989).
 The  molecular  weight  of  the  HPMC  polymer  in  a  matrix
tablet,  and thereof  apparent  viscosity  of  the  hydrated  polymer,  is
important in determining the drug-release properties. It is generally
accepted  that  drug  dissolution  from  tablets  is  slower  for  higher
viscosity grades of HPMC polymers. However, in this study similar
Metformin release rates were observed for tablets containing 36% of
HPMC. 
The mechanism of the drug release in these formulations is
mainly governed by diffusion and as the drug is so highly soluble,
polymer  viscosity  grade  did  not  significantly  affect  the  diffusion
rate.
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In  general,  slower  release  may  be  achieved  with  higher
polymer  levels  or  higher  viscosity  grade  of  HPMC  in  the
formulation. This is mainly due to the longer period of time required
to  reach  the  disentanglement  concentration  at  the  tablet  surface,
which in turn equates  to the greater  resistance to surface erosion,
Such phenomenon is more significant in the gastro-intestinal tract
where attrition on the hydrated surface of the matrix is greater. This
is because drug release does not result solely from active diffusion
through the hydrated polymer, but also from polymer erosion leading
to a thinner hydrated gel layer i.e.  short diffusional path for drug
release.
i. Release profile of Metformin from Metformin hydrochloride
SR Tablets
The  theoretical  release  profile  calculation  is  important  to
evaluate the formulation with respect to release rates and to ascertain
whether it releases the drug in predetermined manner. According to
the  theoretical  release  pattern,  a  once  daily  Metformin  SR
formulation should release 175.6 mg in one hour and 46.3 mg per
hour  for  up  to  8  hours  (Mutalik  &  Hiremath,  2000).  All  the
formulations showed the burst  release  of  Metformin in the initial
hours, which is probably due to faster dissolution of highly water-
soluble  drug  from  the  core  and  its  diffusion  out  of  the  matrix,
forming the pores for the entry of solvent molecule.
Table 9: In vitro Dissolution test of Metformin SR tablets
Time(hrs
)
Percentag
e Release
Percentage
Release F2
Percentage
Release F3
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F1
1 35.3 36.4 43.7
2 44 46.08 48.6
3 53.4 55.48 56.86
4 61.6 64.2 64.66
5 69.4 72.9 74.75
6 78.4 81.6 84.3
7 83.9 88.9 91.03
8 92.8 96.3 98.14
9 96.5 99.5 100
10 99.5 - -
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Fig 11: In vitro Dissolution study of Metformin hydrochloride SR
tablets
ii. Drug Release Kinetics
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To  know  the  mechanism  of  drug  release  from  these
formulations,  the  data  were  treated  according  to  first  order  (log
cumulative  percentage  of  drug  released  versus  time),  Higuchi’s
(cumulative percentage of drug released versus square root of time;
1962),  and  Korsemeyer’s  (log  cumulative  percentage  of  drug
released versus log  time  1983) equations along with a  zero-order
(cumulative percentage of drug release versus time) pattern. In table
10,  the  kinetic  parameters  for  Metformin  HCl  release  from  the
HPMC matrix tablets were presented. As clearly indicated in table
10, the formulations did not follow zero-order or first-order release
patterns. 
The in vitro release profiles of drug from all the formulations
could be best expressed by Higuchi’s equation. Release of drug from
a matrix tablet containing hydrophilic polymers generally involves
factors of diffusion. Diffusion is related to transport of drug from the
dosage  matrix  into  the  in  vitro  study  fluid,  depending  on  the
concentration.  As  gradient  varies,  the  drug  is  released,  and  the
distance for  diffusion  increases.  This  could explain  why the drug
diffuses at a comparatively slower rate as the distance for diffusion
increases, which is referred to as square root kinetics or Higuchi’s
kinetics. To confirm the diffusion mechanism, the data were fitted
into Korsemeyer’s equation (Korsemeyer et  al.,  1983). For matrix
tablets, as n value of near 0.5 indicates diffusion control, and an n
value of near 1.0 indicates erosion or relaxation control. Intermediate
values suggest that diffusion and erosion contribute to the overall
release mechanism (Fassihi & Ritschel, 1993; Peppas, 1985).
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 All  the formulations showed good linearity (R2:  0.974 to 0.992),
indicating  that  the  diffusion  is  the  dominant  mechanism of  drug
release from these formulations.
Table 10: Drug release kinetics of Metformin hydrochloride
Sustained Release tablets
Formulatio
n Code
Zero
order R2
First
order R2
Higuchi’s
kinetics
R2
Korsemeyer’
s kinetics R2
F1 0.9225 0.826 0.9926 0.9886
F2 0.989 0.8076 0.9928 0.989
F3 0.8997 0.8305 0.9747 0.9528
Dissolution kinetics of formulation F1
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Fig12: Zero order release of Metformin 
hydrochloride SR tablets F1
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Fig13: First order release of Metformin hydrochloride 
SR tablets F1
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Fig14: Higuchi’s kinetics of Metformin hydrochloride SR tablets
F1
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Fig15: Korsemeyer’s kinetics of Metformin hydrochloride SR
tablets F1
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Dissolution kinetics of formulation F2
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Fig 16: Zero order release of Metformin hydrochloride SR
tablets F2
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Fig 17: First order release of Metformin 
65
Results and Discussion
hydrochloride SR tablets F2
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Fig18: Higuchi’s kinetics of Metformin hydrochloride SR tablets
F2
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Fig19: Korsemeyer’s kinetics of Metformin hydrochloride SR
tablets
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Dissolution kinetics of formulation F3
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Fig20: Zero order release of Metformin hydrochloride SR tablets
F3
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Fig21: First order release of Metformin hydrochloride SR
tablets F3
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Fig22: Higuchi’s kinetics of Metformin hydrochloride SR tablets
F3
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Fig23: Korsemeyer’s kinetics of Metformin hydrochloride SR
tablets F3
VI.  COMPOSITION OF VARIOUS TRIAL FORMULATIONS
FOR THE IR LAYER CONTAINING GLIPIZIDE
Glipizide  immediate  release  tablets  formulations  were
prepared using kneading method of solid dispersion technique using
sodium starch  glycolate  as  the  disintegrant  and  drug  carrier.  The
composition of the immediate release formulations is given in table
11.
Table 11: Composition of Various Trial Formulations for the IR
Layer Containing Glipizide
Formulation code F4 F5 F6
Drug (mg) 5 5 5
Sodium Starch Glycolate(mg) 10 20 40
Microcrystalline
cellulose(mg) 82 72 52
Talc(mg) 2 2 2
Tartrazine(mg) 1 1 1
Total weight(mg) 100 100 100
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VII. EVALUATION OF GLIPIZIDE IR TABLETS
a. Weight variation test
In a weight variation test,  the pharmacopoeial  limit  (United
States Pharmacopoeia, 2000) for the percentage deviation more than
80mg  is  ±  7.5%.  The  average  percentage  deviation  of  all  tablet
formulations was found to be within the above limit, and hence all
formulations  passed  the  uniformity  of  weight  as  per  official
requirements of the United States Pharmacopoeia (2000). The results
were shown in table 12.
Table 12: Weight variation of Glipizide tablets
S.
No
.
Formulation
code
Weight
range of 20
Tablets (mg)
Average
weight (mg)
Limit
range
(±7.5%)
1 F4 92-97 95 87.88 -102
2 F5 91-97 96 88.8-103.2
3 F6 92-96 95 87.88 -102
b. Hardness test
Formulated Glipizide IR tablets were tested for hardness using
Pfizer  hardness  tester.  The  results  of  hardness  test  were  given in
table 13.
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Table 13: Hardness test of Glipizide IR tablets
S.
No. Formulation code Hardness (kg/cm
2)
1 F4 4
2 F5 3.8
3 F6 3.8
c. Friability
Tablet  hardness  is  not  an  absolute  indicator  of  strength
(Banker & Ander, 1987). Another measure of a tablet’s strength is
friability. Conventional compressed tablets that lose less than 1% of
their  weight  are  generally  considered  acceptable.  In  the  present
study, the percentage of friability for all the formulations was below
1%, indicating that  the  friability  was  within the  prescribed  limits
(Banker & Ander, 1987). The results of friability test were given in
table 14.
Table 14: Friability test of Glipizide IR tablets
S.
No. Formulation code Friability (%)
1 F4 0.48
2 F5 0.63
3 F6 0.57
d. Drug content Uniformity
Glipizide  IR  tablets  are  tested  for  the  drug  content  as
prescribed in the USP. Good uniformity in content was found among
different formulations and the percentage of drug content was more
than 99%. Percentages of drug present in the tablets were given in
the table 15.
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Table 15: Drug content test of Glipizide IR tablets
S.
No.
Formulation
code
Amount of Glipizide
Amount in mg Amount inpercentage
1 F4 4.98 99.6
2 F5 5.15 103
3 F6 5.1 102
e. Disintegration Test
Disintegration test was carried out for formulated Glipizide IR
tablets using the disintegration test apparatus as prescribed in USP.
The results of the disintegration test were given in table 16.
Table 16: Disintegration test of Glipizide IR tablets
S.
No. Formulation code Disintegration Time
1 F4 40 sec
2 F5 28 sec
3 F6 15 sec
f. In vitro Dissolution Study
The release of glipizide from the tablets was studied in 900 ml
of  dissolution  medium using  a  USP dissolution  paddle  assembly
(Lab  India  Disso  2000)  instrument  at  50  rpm and  37±0.5C.  The
dissolution medium used was phosphate buffer (pH 6.8)
Samples  of  dissolution medium were  withdrawn at  suitable
time interval and was then determined spectrophotometrically at 276
nm.  Graph  was  plotted  with  time  vs  percentage  drug  released.
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Percentage release of Glipizide from the formulations F4  and F5 are
given  in  table17  and  percentage  release  of  Glipizide  from
formulation F6 is given in table 18.
Table 17: In vitro Dissolution test of
Glipizide IR tablets (F4& F5)
S. 
No Time(min)
Percentage
Release from F4
Percentage
Release from F5
1 5 52.8 75.8
2 10 64.2 85.6
3 15 81 101
4 20 99.6 -
Table 18: In vitro Dissolution test of Glipizide IR tablets (F6)
S.
No Time(min) Percentage Release from F6
1 2 46.72
2 4 62.8
3 6 73.4
4 8 88.8
5 10 100.2
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Fig24: In vitro Dissolution study of Glipizide IR tablets (F4 & F5)
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Fig25: In vitro Dissolution study of Glipizide IR tablets (F6)
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a. Drug Release Kinetics
To  know  the  mechanism  of  drug  release  from  these
formulations,  the  data  were  treated  according  to  first  order  (log
cumulative  percentage  of  drug  released  versus  time),  Higuchi’s
(cumulative percentage of drug released versus square root of time;
1962),  and  Korsemeyer’s  (log  cumulative  percentage  of  drug
released versus log  time  1983) equations along with a  zero-order
(cumulative percentage of drug release versus time) pattern. In table
19, the kinetic parameters for Glipizide release from the immediate
release tablets are presented. . As clearly indicated in table 19, the
formulations did not follow zero-order or first-order release patterns.
The in vitro release profiles of drug from all the formulations could
be best expressed by Higuchi’s equation and Korsemeyer’s equation.
The optimized formulation F4 can be best  expressed by Higuchi’s
equation
Table 19: Drug release kinetics of Glipizide IR tablets
Formulatio
n Code
Zero
order R2
First
order R2
Higuchi’s
kinetics R2
Korsemeyer’
s kinetics R2
F4 0.9108 0.755 0.9591 0.9532
F5 0.7302 0.859 0.9447 0.9561
F6 0.9102 0.8238 0.9905 0.9908
Dissolution kinetics of formulation F4
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Fig26: Zero order release of Glipizide IR tablets F4
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Fig27: First order release of Glipizide IR tablets F4
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Fig28: Higuchi’s kinetics of Glipizide IR tablets F4
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Fig29: Korsemeyer’s kinetics of Glipizide IR tablets F4
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Dissolution kinetics of formulation F5
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Fig30: Zero order release of Glipizide IR tablets F5
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Fig31: First order release of Glipizide IR tablets F5
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Fig32: Higuchi’s kinetics of Glipizide IR tablets F5
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Fig33: Korsemeyer’s kinetics of Glipizide IR tablets F5
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Dissolution kinetics of formulation F6
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Fig34: Zero order release of Glipizide IR tablets F6
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Fig35: First order release of Glipizide IR tablets F6
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Fig36: Higuchi’s kinetics of Glipizide IR tablets F6
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Fig37: Korsemeyer’s kinetics of Glipizide IR tablets F6
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VIII. COMPOSITION OF BILAYER TABLET OF 
METFORMIN HYDROCHLORIDE (SR) AND GLIPIZIDE 
(IR)
Final  bilayer  tablets  were  prepared  using  optimized
formulations of Metformin hydrochloride (F1) and Glipizide (F4) to
get  the  bilayer  formulation  F7.  Composition  of  bilayer  tablet
containing Metformin hydrochloride (SR) F1 and Glipizide (IR) F4 is
given in table 3 and table 11 respectively.
IX. EVALUATION OF BILAYER TABLET CONTAINING 
METFORMIN HYDROCHLORIDE (SR) AND GLIPIZIDE 
(IR) TABLETS
a. Weight variation test
In a weight variation test,  the pharmacopoeial  limit  (United
States Pharmacopoeia, 2000) for the percentage deviation more than
324mg  is  ±  5%.  The  average  percentage  deviation  of  all  tablet
formulations was found to be within the above limit, and hence all
formulations  passed  the  uniformity  of  weight  as  per  official
requirements of the United States Pharmacopoeia (2000). The results
were shown in table 20.
Table 20: Weight variation of Metformin hydrochloride tablets
and Glipizide Bilayer tablets
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S.
No.
Formulation
code
Weight
range of 20
Tablets
Averag
e
weight
Limit range
(±7.5%)
1 F7 1030-1052 1045mg 992.7-1097.2
b. Hardness test
Formulated Metformin hydrochloride SR tablets were tested
for hardness using Pfizer hardness tester. The results of hardness test
were given in table 21.
Table 21: Hardness test of Bilayer Tablet containing Metformin 
hydrochloride (SR) and Glipizide (IR).
S.
No. Formulation code Hardness (kg/cm
2)
1 F7 6.5
c. Friability
Tablet  hardness  is  not  an  absolute  indicator  of  strength
(Banker & Ander, 1987). Another measure of a tablet’s strength is
friability. Conventional compressed tablets that lose less than 1% of
their  weight  are  generally  considered  acceptable.  In  the  present
study,  the percentage of friability for  the bilayer  formulation was
below 1%, indicating that  the friability was within the prescribed
limits  (Banker & Ander,  1987).  The results  of  friability test  were
given in table 22.
Table 22: Friability test of Metformin hydrochloride (SR) and
Glipizide (IR) tablets
S. No. Formulation code Friability (%)
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1 F7 0.46
d. In vitro Dissolution Study
The release  of  Metformin hydrochloride  and glipizide from
the  bilayer  tablets  was  studied  in  900  ml  of  dissolution  medium
using a USP dissolution paddle assembly (Lab India Disso 2000)
instrument at 50 rpm and 37±0.5°C. The dissolution medium used
was phosphate buffer (pH 6.8)
Samples  of  dissolution medium were  withdrawn at  suitable
time  interval  and  was  then  determined  spectrophotometrically  at
233nm and276  nm respectively.  Graph  was  plotted  with  time  vs
percentage drug released. Percentage release of Metformin from the
formulation  F7 was  given  in  table  23  and  percentage  release  of
Glipizide from formulation F7 was given in table 24.
Table 23: In vitro Dissolution test of Metformin from bilayer
tablets
S. 
No
Time(hrs
)
Percentage Release
of Metformin
1 1 35.3
2 2 44
3 3 53.4
4 4 61.6
5 5 69.4
6 6 78.4
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7 7 83.9
8 8 92.8
9 9 96.5
10 10 99.5
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Fig 38: In vitro Dissolution study of Metformin hydrochloride
From Bilayer tablets
Table 24: In vitro Dissolution test of Glipizide from bilayer
tablets
S. 
No Time(min)
Percentage
Release of
glipizide
1 5 52.8
2 10 64.2
3 15 81
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4 20 99.6
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Fig 39: In vitro Dissolution study of Glipizide from Bilayer
tablets
ii. Drug Release Kinetics
To  know  the  mechanism  of  drugs  released  from  the
formulation,  the  data  were  treated  according  to  first  order  (log
cumulative  percentage  of  drug  released  versus  time),  Higuchi’s
(cumulative percentage of drug released versus square root of time;
1962),  and  Korsemeyer’s  (log  cumulative  percentage  of  drug
released versus log  time  1983) equations along with a  zero-order
(cumulative percentage of drug release versus time) pattern. In table
10, the kinetic parameters for Metformin HCl and Glipizide release
from the Bilayer tablets were presented. As clearly indicated in table
10, the formulations did not follow zero-order or first-order release
patterns. 
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The  in  vitro  release  profiles  of  both  drugs  from  the
formulation could be best expressed by Higuchi’s equation. Release
of  drug  from  a  matrix  tablet  containing  hydrophilic  polymers
generally  involves  factors  of  diffusion.  Diffusion  is  related  to
transport of drug from the dosage matrix into the in vitro study fluid,
depending  on  the  concentration.  As  gradient  varies,  the  drug  is
released, and the distance for diffusion increases. This could explain
why the drug diffuses at a comparatively slower rate as the distance
for diffusion increases, which is referred to as square root kinetics or
Higuchi’s  kinetics.  To confirm the  diffusion  mechanism,  the  data
were fitted into Korsemeyer’s equation (Korsemeyer et  al., 1983).
For matrix tablets, as n value of near 0.5 indicates diffusion control,
and an n value of near 1.0 indicates erosion or relaxation control.
Intermediate values suggest that diffusion and erosion contribute to
the overall  release mechanism (Fassihi  & Ritschel,  1993;  Peppas,
1985).
 The  formulation  showed  good  linearity  (R2:  0.959  to  0.992),
indicating  that  the  diffusion  is  the  dominant  mechanism of  drug
release from this formulation.
Table 25: Drug release kinetics of Metformin hydrochloride
Sustained Release tablets
Formulation
F7
Zero
order R2
First
order R2
Higuchi’s
Plot R2
Korsemeyer’
s plot R2
Metformin
Hydrochlorid
e
0.9225 0.826 0.9926 0.9886
Glipizide 0.9108 0.755 0.9591 0.9532
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Dissolution  kinetics  of  Metformin  hydrochloride  from
formulation F7
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Fig40: Zero order release of Metformin 
hydrochloride SR from bilayer tablets F7
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Fig41: First order release of Metformin hydrochloride 
SR from bilayer tablets F7
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Fig42: Higuchi’s kinetics of Metformin hydrochloride SR from
bilayer tablets F7
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Fig43: Korsemeyer’s kinetics of Metformin hydrochloride SR
from bilayer tablets F7
Dissolution kinetics of Glipizide from formulation F7
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Fig44: Zero order release of Glipizide IR from bilayer tablets F7
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Fig45: First order release of Glipizide IR from bilayer tablets F7
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Fig46: Higuchi’s kinetics of Glipizide IR from bilayer tablets F7
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Fig47: Korsemeyer’s kinetics of Glipizide IR from bilayer tablets
F7
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The  other  evaluation  tests  like  content  uniformity  test,
disintegration test were performed as mentioned for the Metformin
hydrochloride  tablets  and  Glipizide  tablets.  The  results  of
formulations F1 and F4 have been repeated for F7.
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SUMMARY AND CONCLUSION
SUMMARY
Present  work  relates  to  the  development  of  a  bilayer
formulation for the effective treatment of Type 2 Diabetes.
Metformin  hydrochloride  and  Glipizide  were  estimated  at
233nm and 276nm respectively using  UV spectrophotometry  and
they obeyed Beer’s law in the range of 2-10µg/ml.
Compatibility  studies  were  carried  out  for  Metformin
hydrochloride and Glipizide, and with their polymers using FTIR.
No interactions were between the drugs and between the polymers.
Metformin  hydrochloride  SR  tablets  were  prepared  by  direct
compression technique using 3 different grades of HPMC polymer.
The prepared SR tablets were subjected to various evaluation tests
such  as  weight  variation,  drug  content  uniformity,  friability,
hardness,  and in  vitro  dissolution  study.  The  prepared  SR tablets
were  found  to  pass  all  the  evaluation  tests.  Among  the  3
formulations formulation F1 was optimized for preparation of bilayer
tablet as it was found to have better release.
Glipizide  IR  tablets  were  prepared  by  solid  dispersion
technique (kneading method) using SSG as carrier. The prepared IR
tablets  were  subjected  to  various  evaluation  tests  such  as  weight
variation, drug content uniformity, friability, hardness, and in vitro
dissolution study. The prepared IR tablets were found to pass all the
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evaluation  tests.  Among  the  3  formulations  formulation  F4 was
optimized for preparation of bilayer tablet as it was found to have
better release.
The  optimized  formulations  were  used  to  prepare  the  final
bilayer tablet and all the evaluation tests done for SR and IR tablets
were  carried  out  for  the  final  bilayer  tablet.  The  bilayer  tablets
containing Metformin hydrochloride (SR) and Glipizide (IR) were
found to pass all the evaluation tests that were carried out.
CONCLUSION
Metformin  hydrochloride  sustained  release  tablets  and
Glipizide  immediate  release  tablets  were  prepared  using  direct
compression and solid dispersion techniques respectively.
HPMC used as  matrix  forming polymer  for  the  Metformin
layer enables drug release for up to 9-10 hours. Among the different
grades of HPMC no significant difference in the resulting Metformin
release profiles  from the SR layer  of  the tablets  was found. This
indicates  that  the  viscosity  of  the  polymer  does  not  affect  drug
release rate when drug is water soluble and the dose is high.  The
formulation F1 can be preferred as integrity was maintained. 
Glipizide release shows that the dissolution rate of glipizide
can be enhanced considerably by formulating it as a solid dispersion
with  SSG  using  kneading  method.  Incorporation  of  super
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disitnegrants  in  the  solid  dispersions  played  a  critical  role  in
dissolution enhancement.
SR  fixed  dose  bilayer  matrix  tablets  containing
500mgMetformin HCl as SR from one layer and 5mg Glipizide as
IR  from  another  layer  have  been  prepared  by  solid  dispersion
method.  Formulations  F1  and  F4 are  selected  for  preparation  of
bilayer tablet F7. From formulation F7 Metformin hydrochloride and
glipzide  were  found  to  be  released  for  10  hours  and 20  minutes
respectively.
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